Idogen presents the company's technology platform at a scientific congress
Idogen AB (publ) has been invited to present its technology platform for tolerogenic cell therapy at the scientific congress 5th Antigen-Specific Immune Tolerance Summit on 27 January, 2022. This annual meeting involves leading researchers in the field; ranging from American universities to representatives from both large pharmaceutical companies and innovative biotechnology companies. Idogen develops tolerogenic cell therapies for the treatment of unwanted activation of the immune system. In 2021, the company has taken great strides forward with its most advanced development